Public Company News
Innovent Announces PECONDLE® (Picankibart Injection) Phase 3 Study (CLEAR-2) Meets Endpoints, Delivering Superior Long-Term Management Solution for Moderate-to-Severe Psoriasis
SAN FRANCISCO and SUZHOU, China, Dec. 8, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic...
2025-12-09 08:00
1448
AMBITIONS ENTERPRISE MANAGEMENT CO. L.L.C Reports Unaudited Financial Results for the Six Months Ended June 30, 2025
DUBAI, UAE, Dec. 8, 2025 /PRNewswire/ -- AMBITIONS ENTERPRISE MANAGEMENT CO. L.L.C, (the "Company") (Nasdaq: AHMA), a United Arabic Emirates-based MICE (meetings, incentives, conferences, and exhibitions) and tourism services provider, today announced its unaudited financial results for the six m...
2025-12-08 22:15
3110
ALR TECHNOLOGIES TO RELAUNCH THE GLUCURVE PET CGM IN JANUARY 2026
SINGAPORE, Dec. 8, 2025 /PRNewswire/ -- ALR Technologies SG Ltd ("ALRT" or the " Company") (OTC: ALRTF), the diabetes management company, announces the successful completion of internal manufacturing testing on the GluCurve Pet CGM ("GluCurve") showing accuracy results comparative to the leading v...
2025-12-08 22:14
2610
Lunit Submits 510(k) Application for Image-Based Breast Cancer Risk Prediction Model
Submission marks a key regulatory milestone toward bringing SEER-calibrated, imaging-based risk assessment to U.S. screening programs SEOUL, South Korea, Dec. 8, 2025 /PRNewswire/ -- Lunit (KRX:328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced that ...
2025-12-08 22:00
884
AMTD Digital's Subsidiary TGE Executed SPA Successfully to Acquire 50% in The Ritz Carlton Hotel Perth, Australia with a Total Value at A$280 Million
PARIS and NEW YORK and LONDON, Dec. 8, 2025 /PRNewswire/ -- AMTD Group Inc. ("AMTD Group"), AMTD IDEA Group (NYSE: AMTD; SGX: HKB), and The Generation Essentials Group ("TGE" or the "Purchaser", NYSE: TGE), a subsidiary of AMTD Digital Inc. (NYSE: HKD), announce jointly that TGE has entered into ...
2025-12-08 21:58
1920
CTK Launches Dedicated OTC Facility in California, Establishing a Strategic Hub for Global K-beauty Expansion
SEOUL, South Korea, Dec. 8, 2025 /PRNewswire/ -- CTK(KOSDAQ: 260930), a global
K-beauty original design manufacturer (ODM) for cosmetics, has begun operations
at CTK OTC LABORATORIES (COL), its new dedicated over-the-counter (OTC)
manufacturing facility inCorona, California.
2025-12-08 21:30
1057
TOYO Co., Ltd. Acquires Remaining 24.99% Interest in TOYO Solar LLC
TOKYO, Dec. 8, 2025 /PRNewswire/ -- TOYO Co., Ltd
2025-12-08 21:30
1954
Locksley Announces Oversubscribed A$17 Million Placement Lead by U.S. Investors Funding to Accelerate Execution of Locksley's U.S. Mine to Market Strategy
SAN BERNARDINO, Calif., Dec. 8, 2025 /PRNewswire/ -- Locksley Resources Limited (ASX: LKY/OTCQX: LKYRF/ADR: LKYLY) announced the successful completion of a heavily oversubscribed capital raising, securing firm commitments to raise approximatelyA$17 million via a placement of new shares at A$0.24 ...
2025-12-08 21:30
2089
Hyundai Mobis Establishes Additional SW R&D Hub in Bengaluru, India
* Following the establishment of the integrated R&D center in Hyderabad earlier this year, the company is cultivating a locally self-contained SW hub in the IT-centric city of Bengaluru * Securing additional top-tier local software talent to enhance the role of its Indian R&D center… Opening ...
2025-12-08 21:00
836
Autocrypt Announces Product Release of Post-Quantum PKI Product, Pioneering PQC-enabled Solutions for Automotive OEMs
SEOUL, South Korea, Dec. 8, 2025 /PRNewswire/ -- Leading automotive cybersecurity solutions provider AUTOCRYPT announced onDecember 8, 2025, the launch of "AutoCrypt PKI-Vehicles," a new next-generation Public Key Infrastructure (PKI) solution supporting ML-DSA, a post-quantum digital signature ...
2025-12-08 21:00
960
HanchorBio Presents First-in-Human Data of HCB101 Monotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma at ASH 2025
Early Phase 1 monotherapy data demonstrate cytopenia-sparing safety, broad pharmacologic window, and early clinical activity in relapsed/refractory non-Hodgkin lymphoma (NHL) TAIPEI, SHANGHAI, and SAN FRANCISCO, Dec. 8, 2025 /PRNewswire/ -- HanchorBio Inc. (TPEx: 7827), a global clinical-stage b...
2025-12-08 20:00
1121
51Talk Online Education Group Announces New Share Repurchase Program
SINGAPORE, Dec. 8, 2025 /PRNewswire/ -- 51Talk Online Education Group ("51Talk", or the "Company") (NYSE American: COE), a global online education platform with core expertise in English education, today announced that its board of directors has authorized a new share repurchase program under whi...
2025-12-08 19:35
2096
Huya Announces January 7, 2026 Open Beta Launch for Goose Goose Duck Mobile in Chinese Mainland
GUANGZHOU, China, Dec. 8, 2025 /PRNewswire/ -- HUYA Inc. ("Huya" or the "Company") (NYSE: HUYA), a leading game-related entertainment and services provider, today announced that the popular social deduction gameGoose Goose Duck mobile, co‑published by Huya and Kingsoft Shiyou in the Chinese mainl...
2025-12-08 19:30
1012
51Talk Online Education Group Announces Third Quarter 2025 Results
SINGAPORE, Dec. 8, 2025 /PRNewswire/ -- 51Talk Online Education Group ("51Talk" or the "Company") (NYSE American: COE), a global online education platform with core expertise in English education, announced its unaudited results for the third quarter endedSeptember 30, 2025. Third Quarter 2025 F...
2025-12-08 19:30
3475
GC Biopharma Ships First Doses of World's First Recombinant Anthrax Vaccine, 'BARYTHRAX inj.'
- First anthrax vaccine developed using recombinant DNA technology - Annual production capacity of up to 10 million doses at GC Biopharma's facility YONGIN, South Korea, Dec. 8, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a leading global biopharmaceutical company, today announced the first sh...
2025-12-08 14:36
1034
CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting
SHANGHAI, Dec. 7, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that clinical data from its allogeneic BCMA-targeted CAR T-cell product candidate, CT0596, for the treatment of relapsed/r...
2025-12-08 10:08
1516
Median PFS Trending Beyond One Year: Leads Biolabs' LBL-034 Showcases Breakthrough Clinical Data in Oral Presentation at the 2025 ASH Annual Meeting
NANJING, China, Dec. 7, 2025 /PRNewswire/ -- From December 6 to 9, 2025, the 67th Annual Meeting of the American Society of Hematology ("ASH") was held in Orlando, Florida, USA. Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company", Stock Code: 9887.HK) delivered an oral presentation o...
2025-12-08 10:00
980
ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma
SAN FRANCISCO and SUZHOU, China, Dec. 7, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic...
2025-12-08 09:02
1198
CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting
SHANGHAI, Dec. 7, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that clinical data from its allogeneic BCMA-targeted CAR T-cell product candidate, CT0596, for the treatment of relapsed/r...
2025-12-08 08:15
1006
CARsgen's CAR-T Product Zevor-Cel Included in China's Commercial Health Insurance Innovative Drug Catalogue
SHANGHAI, Dec. 7, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced today announced with great pleasure that its independently developed fully human BCMA-targeted CAR-T product, zevorcabtage...
2025-12-07 17:21
1589
Week's Top Stories
Most Reposted
Colebrook Bosson Saunders Launches Lana: An Adaptable Laptop Stand Engineered for Hybrid Work
[Picked up by 305 media titles]
2026-01-12 16:16
CAYIN AI: Revolutionizing Creativity and Global Communication
[Picked up by 300 media titles]
2026-01-12 16:34
Ready Server Announces Strategic Expansion into Japan with AT TOKYO Data Centre
[Picked up by 300 media titles]
2026-01-13 13:16
Novo Nordisk International Operations Commits to Veeva Vault CRM
[Picked up by 290 media titles]
2026-01-08 09:05Courtyard by Marriott Phuket, Patong Beach Resort: The Ultimate Family-Friendly Destination in 2026
[Picked up by 284 media titles]
2026-01-08 12:01
Most Read
J&T Express Hits Record 30 Billion Parcel Volume in 2025 with 22.2% YoY Growth
2026-01-07 06:53
6590
